Efficacy of TNF-α antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis;Efikasnost TNF-α antagoniste i drugih imunomodulatora u terapiji bolesnika sa oftalmološkim manifestacijama Behčetove bolesti i HLA B51 pozitivnih vaskulitisa

Vojnosanitetski Pregled

Volumn 69, Issue 2, 2012, Pages 168-174

  Zlatanović, Gordana ^a   Jovanović, Svetlana ^a   Veselinović, Dragan ^a   Živković, Maja ^a  

^a Klinika za o ne bolesti   (Serbia)

Author keywords

Behcet syndrome; Cyclosporine; Diagnosis; Methotrexate; Retinal diseases; Treatment outcome; Uveitis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; HLA B51 ANTIGEN; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; ARTICLE; BEHCET DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAOCULAR HYPERTENSION; PROGNOSIS; PROSPECTIVE STUDY; RELAPSE; RETINA DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETINA VASCULITIS; RETROSPECTIVE STUDY; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS DISEASE; VITRITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; EYE DISEASES; FEMALE; GLUCOCORTICOIDS; HLA-B51 ANTIGEN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VASCULITIS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; YOUNG ADULT;

EID: 84856685287     PISSN: 00428450     EISSN: None     Source Type: Journal    
DOI: 10.2298/VSP1202168Z     Document Type: Article

References (21)

1. Behçet H. αber rezidivierende aphthφse durch ein Virus verursachte Geschwore am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937; 105: 1152-1157.
2. Marshall SE. Behçet's disease. Best Pract Res Clin Rheumatol 2004; 18(3): 291-311.
3. Gebreselassie D, Spiegel H, Vukmanovic S. Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides. Hum Immunol 2006; 67(11): 894-906.
4. Zierhut M, Mizuki N, Ohno S, Inoko H, Gül A, Onoé K, et al. Immunology and functional genomics of Behçet's disease. Cell Mol Life Sci 2003; 60(9): 1903-1922.
5. Lee MT, Hooper LC, Kump L, Hayashi K, Nussenblatt R, Hooks JJ, et al. Interferon-beta and adhesion molecules (E-selectin and s-intracellular adhesion molecule-1) are detected in sera from patients with retinal vasculitis and are induced in retinal vascular endothelial cells by Toll-like receptor 3 signalling. Clin Exp Immunol 2007; 147(1): 71-80.
6. Okunuki Y, Usui Y, Takeuchi M, Kezuka T, Hattori T, Masuko K, et al. Proteomic surveillance of autoimmunity in Behcet's disease with uveitis: selenium binding protein is a novel autoantigen in Behcet's disease. Exp Eye Res 2007; 84(5): 823-831.
7. Margutti P, Matarrese P, Conti F, Colasanti T, Delunardo F, Capozzi A, et al. Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune- mediated vascular diseases and atherosclerosis. Blood 2008; 111(9): 4559-4570.
8. Yu HG, Lee DS, Seo JM, Ahn JK, Yu YS, Lee WJ, et al. The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Behçet's uveitis. Clin Exp Immunol 2004; 137(2): 437-443.
9. Stanford M, Whittall T, Bergmeier LA, Lindblad M, Lundin S, Shinnick T, et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. Clin Exp Immunol 2004; 137(1): 201-208.
10. Freysdottir J, Lau S, Fortune F. Gammadelta T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999; 118(3): 451-457.
11. Yamamoto JH, Minami M, Inaba G, Masuda K, Mochizuki M. Cellular autoimmunity to retinal specific antigens in patients with Behçet's disease. Br J Ophthalmol 1993; 77(9): 584-589.
12. Davatchi F, Sadeghi Abdollahi B, Shahram F, Nadji A, Chams- Davatchi C, Shams H, et al. Validation of the International Criteria for Behçet's disease (ICBD) in Iran. Int J Rheum Dis 2010; 13(1): 55-60.
13. Aygündüz M, Bavbek N, Oztürk M, Kaftan O, Koşar A, Kirazli S. Serum beta 2-microglobulin reflects disease activity in Behçet's disease. Rheumatol Int 2002; 22(1): 5-8.
14. Coskun B, Saral Y, Gödekmerdan A, Erden I, Coskun N. Activation markers in Behçet's disease. Skinmed 2005; 4(5): 282-286.
15. Takeuchi A, Haraoka H, Hashimoto T. Increased serum alkaline phosphatase activity in Behçet's disease. Clin Exp Rheumatol 1989; 7(6): 619-21.
16. Stanojević-Paović A. Uveitis. Belgrade: School of Medicine; 2008. (Serbian)
17. Bonitsis NG, Alenburg A, Krause L, Stache T, Zouboulis CC. Current concepts in the treatment of Adamantiades-Behçet's disease. Drugs Future 2009; 34(9): 749-763.
18. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67(12): 1656-1662.
19. BenEzra D, Ohno S, Secchi AG, Ali JL. Anterior segment intraocular inflammation guidlines. London: Martin Dunitz, 2000.
20. Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, Gómez Vidal MA, Collantes Estévez E, Ramírez Chamond R, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001; 33(5): 251-255.
21. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004; 138(4): 648-650.